Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 7;4(1):52.
doi: 10.1186/s40792-018-0460-1.

S-1 induced discoid lupus erythematosus-like lesions and long-term complete response for para-aortic lymph node recurrence of pancreatic ductal adenocarcinoma: a case report

Affiliations

S-1 induced discoid lupus erythematosus-like lesions and long-term complete response for para-aortic lymph node recurrence of pancreatic ductal adenocarcinoma: a case report

Ryosuke Yamaga et al. Surg Case Rep. .

Abstract

Background: Metastatic recurrence after resection of pancreatic cancer is considered to be an incurable disease, and discoid lupus erythematosus (DLE)-like lesions are known as a side effect of fluorouracil agents. We report a very rare case of metastatic recurrence of pancreatic cancer in a Japanese man with DLE-like lesions in which long-term complete response was achieved through S-1 monotherapy.

Case presentation: A 65-year-old man who had undergone distal pancreatectomy with splenectomy for pancreatic body cancer and had received adjuvant gemcitabine developed postoperative para-aortic lymph node recurrence 17 months after surgery. S-1 monotherapy was started. About 2 weeks after starting this treatment, he developed an erythematous rash on the face and scalp. DLE was diagnosed by skin biopsy. The eruptions were aggravated by the administration of S-1 and improved during periods of respite from S-1. Yet as CA19-9 was reduced by almost half 1 month after starting S-1 chemotherapy, S-1 chemotherapy was continued at a reduced dose. CA19-9 decreased to within a normal range within 6 months after starting S-1 chemotherapy, and a reduction in lymph node metastasis was detected through imaging. The patient is still alive without recurrence or metastasis 113 months after surgery.

Conclusions: Even in patients with S-1-induced DLE-like lesions, continuation of S-1 is possible if the dose and duration of S-1 are appropriately regulated and medical therapy is administered for the skin lesions. Further investigation into the possible correlation between skin rash and clinical benefit in connection with S-1 is strongly warranted.

Keywords: Chemotherapy; DLE; Long-term survival; Pancreatic cancer; S-1; Skin eruption.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The case report was approved by the Hospital Ethics Committee of Yamagata University Faculty of Medicine.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Competing interests

Wataru Kimura received research funding from Taiho Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co., Ltd, and Public Interest Foundation of Yamagata Health Promotion System.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Histopathological findings of resected specimen of the pancreas. Moderately to poorly differentiated ductal adenocarcinoma was seen in the pancreas
Fig. 2
Fig. 2
Clinical course, postoperative changes of CA19-9, and dose and schedule of S-1 chemotherapy
Fig. 3
Fig. 3
Changes in the appearance and size of para-aortic lymph node metastasis on axial CT imaging and CA19-9 after the start of S-1
Fig. 4
Fig. 4
Erythematous lesions on the face (a) and scalp (b)
Fig. 5
Fig. 5
Pathological findings in an erythematous eruption on the right cheek. a Infiltration of inflammatory cells was seen around the skin appendages (HE, × 100). b Liquefaction degeneration of the basement cells and epidermal atrophy were seen (HE, × 200)
Fig. 6
Fig. 6
Light microscopy findings of kidney biopsy. a Light microscopy showed nodular expansion of mesangium and infiltration of lymphocytes into the interstitium (HE, × 100). b Light microscopy of glomeruli showed increased mesangial matrix and increased mesangial cellularity (HE, × 200)

References

    1. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anti-Cancer Drugs. 1996;7:548–557. doi: 10.1097/00001813-199607000-00010. - DOI - PubMed
    1. Kimura W, Miyata H, Gotoh M, Hirai I, Kenjo A, Kitagawa Y, et al. A pancreaticoduodenectomy risk model derived from 8575 cases from a national single-race population (Japanese) using a web-based data entry system: the 30-day and in-hospital mortality rates for pancreaticoduodenectomy. Ann Surg. 2014;259:773–780. doi: 10.1097/SLA.0000000000000263. - DOI - PubMed
    1. Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) Lancet. 2016;388:248–257. doi: 10.1016/S0140-6736(16)30583-9. - DOI - PubMed
    1. Todaka A, Fukutomi A, Boku N, Onozawa Y, Hironaka S, Yasui H, et al. S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure. Jpn J Clin Oncol. 2010;40:567–572. doi: 10.1093/jjco/hyq005. - DOI - PubMed
    1. Morizane C, Okusaka T, Furuse J, Ishii H, Ueno H, Ikeda M, et al. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2009;63:313–319. doi: 10.1007/s00280-008-0741-7. - DOI - PubMed

LinkOut - more resources